Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

Is pre-transplant intervention warranted in patients with MRD+ AML in CR1?

Tapan Kadia, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents evidence for intervention before allogeneic stem-cell transplantation (alloSCT) in patients with acute myeloid leukemia (AML) in first complete remission (CR1) with detectable measurable residual disease (MRD). Dr Kadia highlights that pre-transplant MRD positivity is linked to higher relapse risk and inferior survival. He also emphasizes the potential of effective upfront therapy, such as the cladribine, low-dose cytarabine and venetoclax regimen (NCT03586609), to eradicate MRD, highlighting that clearing MRD, as seen in studies including RELAZA2 (NCT01462578), is associated with improved outcomes. This presentation took place at the 8th International Workshop on Acute Leukemias (iwAL) 2026, held in Cambridge, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.